Innocare Announces the Results of P-II Study for TYK2 Inhibitor ICP-332 in Patients with Atopic Dermatitis
Shots:
- The P-II study evaluating safety, efficacy, PK and PD of ICP-332 in patients with moderate-to-severe atopic dermatitis
- The result of the study demonstrated efficacy and safety in a 4-week treatment, achieving significant improvement in EASI scores, with a mean percentage change of 78.2% & 72.5% for 80mg & 120mg dosing groups, respectively
- The study revealed ICP-332's positive impact on multiple efficacy endpoints incl. EASI 50, EASI 75, EASI 90, and IGA 0/1. The safety & tolerability of the drug were comparable to that of PBO
Ref: Innocare | Image: Innocare
Related News:- InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
